Question-and-Answer Session
Operator
(Operator instructions) And your first question comes from the line of Joel Sendek with Lazard Capital Markets. Please proceed.
Joel Sendek – Lazard Capital Markets
Hi, thanks a lot. So – I have two questions. The first is on the filing. I was expecting filing a little bit earlier, but is the issue that you have to meet with the FDA, you couldn't get a meeting? And my other related question is have you had a meeting already with them?
Mitchell Steiner
Those are your two questions?
Joel Sendek – Lazard Capital Markets
I guess I have another one after that.
Mitchell Steiner
I will answer that question. We will take the second question. The answer is we're ready to go. But it would be foolish to have a – to file to NDA without a pre-NDA meeting. And as you know the FDA [ph] kind of busy and we have been working aggressively to get on the schedule. So we are efficiently scheduled for an FDA meeting, and a pre-NDA meeting with the FDA in October. And as you know that meeting is primarily a box-checking meeting in the sense that you meet with the FDA to make sure that you have all the studies and all the components of those studies they're going to be required for the review. And so, we do plan to file electronically. And we've been working on for the last 18months. And as you know we own the NDA for Fareston 60 mg, we've been able to heavily cross reference that. So, really, sort of an FDA scheduling thing and being prudent about making sure we meet with the FDA before we file.
Joel Sendek – Lazard Capital Markets
Okay, great. Second question has to do with the Sarcopenia. You indicated that it's maybe the same size as marketed as osteoporosis, which is quite a bold statement I think. I'm wondering does Merck share that view and what's the served market as far as revenues? I'm assuming that you're talking about incidence of disease, but do you know what the served market is, as far as product sales or what people use for that right now?
Mitchell Steiner
Yes, Joel, let me answer the first question, the first part of that for sure. Merck definitely see this as very opportunistic. We purposefully are not stating market size right now, because we don't think it's appropriate at this point, but we are linking it in order to kind of work our own – do our own diligence here and the diligence that has been conducted on market research through the relationship with Merck and GTx. It's very clear to us that it is the size of the osteoporosis market. Perhaps maybe even a little bit bigger, but we are purposefully not going into numbers at this point until we get a little bit further along. Just give you more clarity how we view – how it's viewed, sarcopenia sometimes is called frailty. The frailty is the muscle loss occurs with aging. And interestingly, the muscle loss occurs with aging can also lead to not only loss of independence and mobility and that kind of stuff, but also to falls.
- To read the full transcript on Seeking Alpha, click here »
